Critical
Everolimus × Posaconazole
mTOR kinase inhibitor – immunosuppressant and antineoplastic×Second-generation systemic triazole antifungal
Mechanism
Strong CYP3A4 inhibitor. Everolimus rises 9-fold.
Symptoms
Immunosuppression, nephrotoxicity.
Management
Combination contraindicated.
Check the full regimen, not just this pair
Opens the checker with these two drugs prefilled. Add the rest of the regimen and recompute additive risks.
Sources
- EMA: Certican (everolimus) SmPC (2024)– EMA EPAR Certican